Last reviewed · How we verify

Regular management+Levosimendan

Qilu Hospital of Shandong University · FDA-approved active Small molecule

Levosimendan is a calcium sensitizer that increases the force of cardiac muscle contraction without increasing oxygen consumption, used as adjunctive therapy in acute decompensated heart failure.

Levosimendan is a calcium sensitizer that increases the force of cardiac muscle contraction without increasing oxygen consumption, used as adjunctive therapy in acute decompensated heart failure. Used for Acute decompensated heart failure (adjunctive therapy), Cardiogenic shock.

At a glance

Generic nameRegular management+Levosimendan
SponsorQilu Hospital of Shandong University
Drug classCalcium sensitizer / Inotropic agent
TargetCardiac troponin C
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Levosimendan binds to cardiac troponin C and enhances the sensitivity of contractile proteins to calcium, thereby improving myocardial contractility. It also has vasodilatory properties through opening of ATP-sensitive potassium channels. When combined with regular management protocols, it provides inotropic support in acute heart failure while reducing systemic and pulmonary vascular resistance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: